Brief: UCB Says Its DZP Shows 'Efficacy' Across Multiple Clinical Endpoints

UCB SA

12/06/2025 06:13

June 12 (Reuters) - UCB SA UCB.BR:

DAPIROLIZUMAB PEGOL PHASE 3 DATA IN SLE PRESENTED AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR) SHOW IMPROVEMENT IN FATIGUE AND REDUCTION IN DISEASE ACTIVITY

DZP SHOWED CONSISTENT IMPROVEMENTS IN FATIGUE, A COMMON AND DEBILITATING SYMPTOM OF SYSTEMIC LUPUS ERYTHEMATOSUS

DAPIROLIZUMAB PEGOL (DZP) SHOWED EFFICACY ACROSS MULTIPLE CLINICAL ENDPOINTS IN PHOENYCS GO STUDY

Source text: ID:nGNX7ck5dq

Further company coverage: UCB.BRBIIB.O

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))